Matinas BioPharma Awarded up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients
November 20, 2020 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
November 19, 2020 16:15 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on developing next generation therapeutics...
Matinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights
November 06, 2020 07:00 ET
|
Matinas BioPharma Holdings, Inc.
EnACT study of MAT2203 in cryptococcal meningitis received unanimous Data and Safety Monitoring Board (DSMB) recommendation to proceed into second patient cohort – ENHANCE-IT study of MAT9001 against...
Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2020 Financial and Operational Results on November 6, 2020
October 23, 2020 07:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a...
Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
October 19, 2020 06:30 ET
|
Matinas BioPharma Holdings, Inc.
– DSMB evaluated both safety and efficacy data in recommending cohort progression – – Enrollment in second cohort of patients expected to commence imminently with next DSMB evaluation anticipated...
Matinas BioPharma Announces Positive End of Phase 2 Meeting with the FDA for MAT9001 in Severe Hypertriglyceridemia (SHTG)
September 15, 2020 07:00 ET
|
Matinas BioPharma Holdings, Inc.
- FDA Agreement to Move Directly into Phase 3 - - FDA to Require a Single Phase 3 Trial of 12 Weeks Duration to Support Efficacy for an NDA filing in SHTG - BEDMINSTER, N.J., Sept. 15, 2020 (GLOBE...
Matinas BioPharma Appoints Industry Veteran Natasha Giordano to Board of Directors
September 14, 2020 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced the appointment of Natasha Giordano to its Board of Directors as an...
Matinas BioPharma to Participate on Anti-Fungal CEO Panel During the M-VEST Virtual Conference Series Sponsored by Maxim Group
September 10, 2020 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...
Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa®
August 27, 2020 16:05 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has completed enrollment in the ENHANCE-IT Study (Pharmacodynamic...
Matinas BioPharma to Participate in Two Upcoming Virtual Investor Conferences
August 26, 2020 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a...